135 related articles for article (PubMed ID: 38110538)
1. Progression of albuminuria and podocyte injury in focal segmental glomerulosclerosis inhibited by enhanced glycosphingolipid GM3 via valproic acid.
Kawashima N; Naito S; Nagane M; Yamashita T; Nakayama KI
Sci Rep; 2023 Dec; 13(1):22487. PubMed ID: 38110538
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Levels of Glycosphingolipid GM3 Delay the Progression of Diabetic Nephropathy.
Naito S; Nakayama K; Kawashima N
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511118
[TBL] [Abstract][Full Text] [Related]
3. Glycosphingolipid GM3 prevents albuminuria and podocytopathy induced by anti-nephrin antibody.
Kawashima N; Naito S; Hanamatsu H; Nagane M; Takeuchi Y; Furukawa JI; Iwasaki N; Yamashita T; Nakayama KI
Sci Rep; 2022 Sep; 12(1):16058. PubMed ID: 36163359
[TBL] [Abstract][Full Text] [Related]
4. Decreased GM3 correlates with proteinuria in minimal change nephrotic syndrome and focal segmental glomerulosclerosis.
Naito S; Kawashima N; Ishii D; Fujita T; Iwamura M; Takeuchi Y
Clin Exp Nephrol; 2022 Nov; 26(11):1078-1085. PubMed ID: 35804208
[TBL] [Abstract][Full Text] [Related]
5. Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria.
Dai C; Stolz DB; Kiss LP; Monga SP; Holzman LB; Liu Y
J Am Soc Nephrol; 2009 Sep; 20(9):1997-2008. PubMed ID: 19628668
[TBL] [Abstract][Full Text] [Related]
6. Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling.
Qiao Y; Wang P; Chang M; Chen B; Ge Y; Malhotra DK; Dworkin LD; Gong R
Clin Sci (Lond); 2020 Apr; 134(7):695-710. PubMed ID: 32167144
[TBL] [Abstract][Full Text] [Related]
7. Activation of RhoA in podocytes induces focal segmental glomerulosclerosis.
Zhu L; Jiang R; Aoudjit L; Jones N; Takano T
J Am Soc Nephrol; 2011 Sep; 22(9):1621-30. PubMed ID: 21804090
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Importin- α -Mediated Nuclear Localization of Dendrin Attenuates Podocyte Loss and Glomerulosclerosis.
Empitu MA; Kikyo M; Shirata N; Yamada H; Makino SI; Kadariswantiningsih IN; Aizawa M; Patrakka J; Nishimori K; Asanuma K
J Am Soc Nephrol; 2023 Jul; 34(7):1222-1239. PubMed ID: 37134307
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of ACTN4 Leads to Podocyte Vulnerability and Proteinuric Glomerulosclerosis.
Feng D; Kumar M; Muntel J; Gurley SB; Birrane G; Stillman IE; Ding L; Wang M; Ahmed S; Schlondorff J; Alper SL; Ferrante T; Marquez SL; Ng CF; Novak R; Ingber DE; Steen H; Pollak MR
J Am Soc Nephrol; 2020 Jul; 31(7):1479-1495. PubMed ID: 32540856
[TBL] [Abstract][Full Text] [Related]
10. The long noncoding RNA LOC105374325 causes podocyte injury in individuals with focal segmental glomerulosclerosis.
Hu S; Han R; Shi J; Zhu X; Qin W; Zeng C; Bao H; Liu Z
J Biol Chem; 2018 Dec; 293(52):20227-20239. PubMed ID: 30389788
[TBL] [Abstract][Full Text] [Related]
11. Podocyte expression of nonmuscle myosin heavy chain-IIA decreases in idiopathic nephrotic syndrome, especially in focal segmental glomerulosclerosis.
Miura K; Kurihara H; Horita S; Chikamoto H; Hattori M; Harita Y; Tsurumi H; Kajiho Y; Sawada Y; Sasaki S; Igarashi T; Kunishima S; Sekine T
Nephrol Dial Transplant; 2013 Dec; 28(12):2993-3003. PubMed ID: 24042022
[TBL] [Abstract][Full Text] [Related]
12. New Anti-Nephrin Antibody Mediated Podocyte Injury Model Using a C57BL/6 Mouse Strain.
Takeuchi K; Naito S; Kawashima N; Ishigaki N; Sano T; Kamata K; Takeuchi Y
Nephron; 2018; 138(1):71-87. PubMed ID: 28965116
[TBL] [Abstract][Full Text] [Related]
13. Podocyte-specific RAP1GAP expression contributes to focal segmental glomerulosclerosis-associated glomerular injury.
Potla U; Ni J; Vadaparampil J; Yang G; Leventhal JS; Campbell KN; Chuang PY; Morozov A; He JC; D'Agati VD; Klotman PE; Kaufman L
J Clin Invest; 2014 Apr; 124(4):1757-69. PubMed ID: 24642466
[TBL] [Abstract][Full Text] [Related]
14. RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis.
Guo J; Ananthakrishnan R; Qu W; Lu Y; Reiniger N; Zeng S; Ma W; Rosario R; Yan SF; Ramasamy R; D'Agati V; Schmidt AM
J Am Soc Nephrol; 2008 May; 19(5):961-72. PubMed ID: 18256352
[TBL] [Abstract][Full Text] [Related]
15. Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis.
Daehn I; Casalena G; Zhang T; Shi S; Fenninger F; Barasch N; Yu L; D'Agati V; Schlondorff D; Kriz W; Haraldsson B; Bottinger EP
J Clin Invest; 2014 Apr; 124(4):1608-21. PubMed ID: 24590287
[TBL] [Abstract][Full Text] [Related]
16. Fibrinogen links podocyte injury with Toll-like receptor 4 and is associated with disease activity in FSGS patients.
Wang H; Zheng C; Xu X; Zhao Y; Lu Y; Liu Z
Nephrology (Carlton); 2018 May; 23(5):418-429. PubMed ID: 28407405
[TBL] [Abstract][Full Text] [Related]
17. Focal segmental glomerulosclerosis; why does it occur segmentally?
Nagata M; Kobayashi N; Hara S
Pflugers Arch; 2017 Aug; 469(7-8):983-988. PubMed ID: 28664408
[TBL] [Abstract][Full Text] [Related]
18. Bradykinin receptor 1 activation exacerbates experimental focal and segmental glomerulosclerosis.
Pereira RL; Buscariollo BN; Corrêa-Costa M; Semedo P; Oliveira CD; Reis VO; Maquigussa E; Araújo RC; Braga TT; Soares MF; Moura IC; Malheiros DM; Filho AP; Keller AC; Câmara NO
Kidney Int; 2011 Jun; 79(11):1217-27. PubMed ID: 21412216
[TBL] [Abstract][Full Text] [Related]
19. Loss of phosphatidylserine flippase β-subunit Tmem30a in podocytes leads to albuminuria and glomerulosclerosis.
Liu W; Peng L; Tian W; Li Y; Zhang P; Sun K; Yang Y; Li X; Li G; Zhu X
Dis Model Mech; 2021 Jun; 14(6):. PubMed ID: 34080006
[TBL] [Abstract][Full Text] [Related]
20. Btg2 Promotes Focal Segmental Glomerulosclerosis via Smad3-Dependent Podocyte-Mesenchymal Transition.
Dan Hu Q; Wang HL; Liu J; He T; Tan RZ; Zhang Q; Su HW; Kantawong F; Lan HY; Wang L
Adv Sci (Weinh); 2023 Nov; 10(32):e2304360. PubMed ID: 37749872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
